Danvatirsen
- Generic Name
- Danvatirsen
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1402357-06-5
- Unique Ingredient Identifier
- 31N550RD05
- Background
Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).
- Associated Conditions
- -
- Associated Therapies
- -
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Flamingo Therapeutics NV
- Target Recruit Count
- 81
- Registration Number
- NCT05814666
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸University of Maryland Baltimore, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸UT Southwestern Medical Center/Simmons Comprehensive Cancer Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath